AU2010241564B2 - Novel therapeutic treatments using centhaquin - Google Patents

Novel therapeutic treatments using centhaquin Download PDF

Info

Publication number
AU2010241564B2
AU2010241564B2 AU2010241564A AU2010241564A AU2010241564B2 AU 2010241564 B2 AU2010241564 B2 AU 2010241564B2 AU 2010241564 A AU2010241564 A AU 2010241564A AU 2010241564 A AU2010241564 A AU 2010241564A AU 2010241564 B2 AU2010241564 B2 AU 2010241564B2
Authority
AU
Australia
Prior art keywords
centhaquin
clonidine
pain
rats
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010241564A
Other languages
English (en)
Other versions
AU2010241564A1 (en
AU2010241564A2 (en
Inventor
Anil Gulati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midwestern University Glendale
Original Assignee
Midwestern University Downers Grove
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Downers Grove, Midwestern University Glendale filed Critical Midwestern University Downers Grove
Publication of AU2010241564A1 publication Critical patent/AU2010241564A1/en
Publication of AU2010241564A2 publication Critical patent/AU2010241564A2/en
Application granted granted Critical
Publication of AU2010241564B2 publication Critical patent/AU2010241564B2/en
Priority to AU2014256346A priority Critical patent/AU2014256346B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2010241564A 2009-04-30 2010-04-29 Novel therapeutic treatments using centhaquin Active AU2010241564B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014256346A AU2014256346B2 (en) 2009-04-30 2014-10-29 Novel therapeutic treatments using centhaquin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17425709P 2009-04-30 2009-04-30
US61/174,257 2009-04-30
PCT/US2010/032942 WO2010127096A2 (en) 2009-04-30 2010-04-29 Novel therapeutic treatments using centhaquin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014256346A Division AU2014256346B2 (en) 2009-04-30 2014-10-29 Novel therapeutic treatments using centhaquin

Publications (3)

Publication Number Publication Date
AU2010241564A1 AU2010241564A1 (en) 2011-11-17
AU2010241564A2 AU2010241564A2 (en) 2012-10-04
AU2010241564B2 true AU2010241564B2 (en) 2014-07-31

Family

ID=43032771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010241564A Active AU2010241564B2 (en) 2009-04-30 2010-04-29 Novel therapeutic treatments using centhaquin

Country Status (10)

Country Link
US (2) US20120083447A1 (enExample)
EP (1) EP2424529B1 (enExample)
JP (2) JP5498571B2 (enExample)
CN (2) CN103989682B (enExample)
AU (1) AU2010241564B2 (enExample)
BR (1) BRPI1013903B1 (enExample)
CA (1) CA2759791C (enExample)
ES (1) ES2614813T3 (enExample)
PL (1) PL2424529T3 (enExample)
WO (1) WO2010127096A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
US20150250782A1 (en) * 2012-08-31 2015-09-10 Pharmazz, Inc. Methods and Compositions for Hypotensive Resuscitation
WO2016061583A1 (en) * 2014-10-17 2016-04-21 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
CN112469474A (zh) * 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
WO2022240964A1 (en) * 2021-05-11 2022-11-17 Pharmazz, Inc. Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) * 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ １―ｍ―トリル―４―（Ｂ―２―キノリエチル）―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) * 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
EP0126327A1 (en) 1983-04-26 1984-11-28 Frank J. Macri Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20070066568A1 (en) 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20050009847A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US7906140B2 (en) 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
JP2009530407A (ja) 2006-03-23 2009-08-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
PL2182977T3 (pl) 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
US20150250782A1 (en) 2012-08-31 2015-09-10 Pharmazz, Inc. Methods and Compositions for Hypotensive Resuscitation
EP3019242B1 (en) 2013-07-08 2020-08-19 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists

Also Published As

Publication number Publication date
US20180085461A1 (en) 2018-03-29
AU2010241564A1 (en) 2011-11-17
PL2424529T3 (pl) 2017-06-30
WO2010127096A2 (en) 2010-11-04
JP2014141502A (ja) 2014-08-07
BRPI1013903B1 (pt) 2020-03-03
JP5498571B2 (ja) 2014-05-21
US20120083447A1 (en) 2012-04-05
CN103989682A (zh) 2014-08-20
WO2010127096A3 (en) 2011-03-24
EP2424529A2 (en) 2012-03-07
CN103989682B (zh) 2016-03-30
EP2424529A4 (en) 2012-11-28
EP2424529B1 (en) 2016-12-28
US10828368B2 (en) 2020-11-10
CA2759791A1 (en) 2010-11-04
CN102458399B (zh) 2014-04-23
CN102458399A (zh) 2012-05-16
JP2012525422A (ja) 2012-10-22
JP5727642B2 (ja) 2015-06-03
BRPI1013903A2 (pt) 2016-07-19
AU2010241564A2 (en) 2012-10-04
CA2759791C (en) 2018-04-10
ES2614813T3 (es) 2017-06-02

Similar Documents

Publication Publication Date Title
US10828368B2 (en) Therapeutic treatments using centhaquin
US10112981B2 (en) Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
JP2005513033A (ja) 麻薬鎮痛剤を増強する方法及び組成物
US20100113469A1 (en) Combination therapy for the treatment-of lower urinary tract symptoms
JP5536198B2 (ja) 糖尿病性ケトアシドーシスを治療するための方法および組成物
JP2025170421A (ja) 全身性硬化症の予防または治療用薬学的組成物
EP2330903A1 (en) Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist
AU2014256346B2 (en) Novel therapeutic treatments using centhaquin
Lavhale et al. Endothelin modulates the cardiovascular effects of clonidine in the rat
US20100022574A1 (en) Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US20080188508A1 (en) Methods and Therapies for Potentiating a Therapeutic Action of an Opioid Receptor Agonist and Inhibiting and/or Reversing Tolerance to Opioid Receptor Agonists
WO2020018839A1 (en) Compounds and methods for synergistic activation of m channels

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 SEP 2012

FGA Letters patent sealed or granted (standard patent)